NCT05074719 (IICov19PRS) is a clinical trial in SARS-CoV-2 Infection, sponsored by University of Washington.

Who is sponsoring NCT05074719?

NCT05074719 is sponsored by University of Washington.

What condition does NCT05074719 study?

NCT05074719 studies SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome).

Is NCT05074719 still recruiting?

NCT05074719 is currently completed. Last updated 15 December 2021.

Last reviewed 2021-12-15 · How we verify

NCT05074719: IICov19PRS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

Completed Last updated 15 December 2021

What this trial tests

trial in SARS-CoV-2 Infection in 155 participants. Completed in 31 October 2021.

Timeline

10 December 2020

Primary endpoint
31 October 2021

31 October 2021

Quick facts

Lead sponsor	University of Washington
Status	Completed
Study type	OBSERVATIONAL
Enrollment	155
Start date	10 December 2020
Primary completion	31 October 2021
Estimated completion	31 October 2021
Sites	1 location across United States

Conditions studied

SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
COVID-19 — all drugs for COVID-19 →
Coronavirus Infection — all drugs for Coronavirus Infection →
SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →

Sponsor

University of Washington

Who can join

10 and older, any sex, with SARS-CoV-2 Infection or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical trials of prevention modalities for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and coronavirus disease (COVID-19) and pneumonia are underway under separate protocol(s) for close contacts (i.e., household contacts, \[e.g.,3502\]) of infectious (index) individuals (3502-01). Characterizing the index individuals within households will ascertain the risk of exposure for the contact participant. These data will be used to strengthen the precision of efficacy estimates. This ancillary observational study will assess the cofactors for infectiousness among index individuals whose close contacts are enrolled in COVID-19 prevention clinical trials. Additionally, this study will assess post-acute sequelae of SARS-CoV-2 infection in index individuals that are more than two weeks past their initial diagnosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Concordance between SARS-CoV-2 index individuals and their household contacts on index individual COVID-19 transmission cofactors: a comparison of self-reported and contact-reported information.
Dahl AM, Brown CE, Brown ER, O'Brien MP, et al · · 2024 · PMID 38566051 · DOI 10.1186/s12889-024-18371-7

Verify or expand the search:

Other recruiting trials for SARS-CoV-2 Infection

Currently open trials in the same condition.

NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05074719 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 15 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05074719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing